Highlights

  • 4DX shares closed at $3.67, down 4.18% on 24 August 2026
  • Announced a strategic OEM and reseller Partnership with Azra AI in August
  • Partnership connects lung-imaging findings with earlier identification of patients needing follow-up care
  • Continuing separate partnership with RevealDx on AI-based lung-cancer risk assessment

4DMEDICAL Ltd (ASX:4DX) shares closed at $3.67, down 4.18% on 24 August 2026. The stock remains one to watch as the healthcare technology company continues to broaden its respiratory-imaging platform through new partnerships in AI-enabled clinical workflows.

About 4DMEDICAL Ltd

4DMEDICAL Ltd is a healthcare technology company that has developed a functional lung-imaging platform designed to provide detailed, dynamic assessments of lung function using advanced imaging techniques. The company's core technology aims to give clinicians more precise information about regional lung function than traditional imaging methods, supporting improved diagnosis and monitoring of respiratory conditions. Beyond its core imaging technology, 4DMedical has increasingly pursued a strategy of forming partnerships with complementary healthcare software providers, aiming to integrate its imaging findings into broader clinical workflows that support patient identification, care coordination and follow-up management. This approach reflects a recognition that imaging technology alone often needs to be connected with Downstream clinical processes in order to deliver its full value to health systems. As a relatively early-stage healthcare technology company, 4DMedical's growth strategy depends heavily on expanding adoption of its imaging platform among health-system customers, as well as successfully executing on partnerships that extend its technology into adjacent areas of clinical decision support.

Key Developments

4DMedical continues expanding its respiratory-imaging platform through partnerships that combine its functional lung-imaging technology with complementary healthcare software. In August, the company announced a strategic OEM and reseller partnership with Azra AI, allowing 4DMedical to offer Azra's patient-identification and care-coordination platform to its health-system customers. The agreement is designed to connect lung-imaging findings with earlier identification of patients requiring follow-up care, addressing an important gap in the clinical pathway between imaging results and the coordination of subsequent patient management. This type of partnership can help strengthen 4DMedical's value proposition to health systems by extending its offering beyond imaging alone into a more complete clinical workflow solution. 4DMedical is also progressing its partnership with RevealDx around AI-based lung-cancer risk assessment, another initiative aimed at applying artificial intelligence to enhance the clinical Utility of imaging data. These developments broaden the company's healthcare platform beyond imaging into AI-enabled clinical workflows, reflecting a strategic shift toward positioning 4DMedical as a broader clinical technology partner rather than solely an imaging-technology provider, a transition that could support longer-term adoption and Revenue growth if successfully executed.

Conclusion

4DMedical's new partnership with Azra AI, alongside its ongoing collaboration with RevealDx, reflects a clear strategic push to extend the company's respiratory-imaging platform into broader AI-enabled clinical workflows. While the share price declined on the day, these partnerships represent important steps in building out a more comprehensive healthcare technology offering. The success of this strategy will ultimately depend on adoption among health-system customers and the company's ability to convert these partnerships into meaningful commercial outcomes.